Neurobiological Technologies Equity 2024

Neurobiological Technologies Aktienanalyse

What does Neurobiological Technologies do?

Neurobiological Technologies Inc. (NTI) is an American company specializing in the research and development of new drugs for neurological disorders. It was founded in the 1980s by a team of neuroscientists focused on the treatment of stroke and traumatic brain injuries. NTI's business model is based on identifying promising targets within the nervous system and developing novel drugs that specifically target these targets. Through close collaboration with academic and clinical partners, NTI can rapidly develop new technologies and therapeutic approaches and bring them into the clinical phase. NTI is divided into various divisions focusing on different neurological disorders such as Parkinson's disease, Alzheimer's disease, and epilepsy. Each division is staffed with experts who have extensive experience in their respective research fields and collaborate closely with external partners. Over the years, NTI has developed several products at different stages of clinical development. One of the most promising products is XERECEPT, a synthetic peptide used for the treatment of brain tumors. The drug has shown promising results in clinical trials and has been submitted for market approval in the USA and Europe. Another promising product is Viprinex, a novel medication for the treatment of stroke patients. Viprinex is currently being tested in phase III of clinical development, and the results of the clinical trials are promising, suggesting that the drug may be approved in the near future. NTI is a pioneer in the field of neurology and has received several awards and accolades for its work. The company is also recognized in the academic community and has established partnerships with leading universities and research institutions. Overall, NTI is an innovative company specializing in the development of novel drugs for neurological disorders. It has achieved impressive successes in recent decades and is considered one of the most promising development companies in the field of neurology. Neurobiological Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Neurobiological Technologies's Equity

Neurobiological Technologies's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Neurobiological Technologies's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Neurobiological Technologies's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Neurobiological Technologies's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Neurobiological Technologies’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Neurobiological Technologies stock

What is the equity of Neurobiological Technologies this year?

Neurobiological Technologies has equity of 0 USD this year.

What was the equity of Neurobiological Technologies compared to the previous year?

The equity of Neurobiological Technologies has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Neurobiological Technologies?

A high equity is advantageous for investors of Neurobiological Technologies as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Neurobiological Technologies?

A low equity can be a risk for investors of Neurobiological Technologies, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Neurobiological Technologies affect the company?

An increase in equity of Neurobiological Technologies can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Neurobiological Technologies affect the company?

A reduction in equity of Neurobiological Technologies can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Neurobiological Technologies?

Some factors that can affect the equity of Neurobiological Technologies include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Neurobiological Technologies so important for investors?

The equity of Neurobiological Technologies is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Neurobiological Technologies take to change the equity?

To change equity, Neurobiological Technologies can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Neurobiological Technologies pay?

Over the past 12 months, Neurobiological Technologies paid a dividend of 0.93 USD . This corresponds to a dividend yield of about 930,000 %. For the coming 12 months, Neurobiological Technologies is expected to pay a dividend of 0.93 USD.

What is the dividend yield of Neurobiological Technologies?

The current dividend yield of Neurobiological Technologies is 930,000 %.

When does Neurobiological Technologies pay dividends?

Neurobiological Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Neurobiological Technologies?

Neurobiological Technologies paid dividends every year for the past 0 years.

What is the dividend of Neurobiological Technologies?

For the upcoming 12 months, dividends amounting to 0.93 USD are expected. This corresponds to a dividend yield of 930,000 %.

In which sector is Neurobiological Technologies located?

Neurobiological Technologies is assigned to the '-' sector.

Wann musste ich die Aktien von Neurobiological Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Neurobiological Technologies from 12/27/2012 amounting to 0.05 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2012.

When did Neurobiological Technologies pay the last dividend?

The last dividend was paid out on 12/27/2012.

What was the dividend of Neurobiological Technologies in the year 2023?

In the year 2023, Neurobiological Technologies distributed 0 USD as dividends.

In which currency does Neurobiological Technologies pay out the dividend?

The dividends of Neurobiological Technologies are distributed in USD.